Your email has been successfully added to our mailing list.

×
-1.54559505410595E-05 0.0092735703245749 0.0278207109737248 0.044822256568779 0.244204018547141 0.217928902627512 0.298299845440495 0.329211746522411
Stock impact report

Evofem stock rallies as FDA approves birth-control gel [MarketWatch]

Evofem Biosciences, Inc (EVFM)  More Company Research Source: MarketWatch
Last evofem biosciences, inc earnings: 3/12 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: evofem.com
PDF Evofem Biosciences Inc. stock rallied in the extended session Friday after the biotech company said the Food and Drug Administration approved its birth-control gel. Evofem shares surged 23% after hours, following a 3.7% rise to close the regular session at $4.99. The company said the FDA approved Phexxi, a gel that uses lactic acid and citric acid to put vaginal pH levels in the 3.5 to 4.5 range, which is inhospitable to sperm. Evofem said it is working to have Phexxi covered under the Affordable Care Act. [Read more]
Impact snapshot Event time: EVFM
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
EVFM alerts
from News Quantified
Opt-in for
EVFM alerts

from News Quantified
Opt-in for
EVFM alerts

from News Quantified